A UCLA-led international study found that the investigational oral drug daraxonrasib significantly improved survival and tumor response in patients with metastatic pancreatic cancer compared to standard chemotherapy. - Patients taking daraxonrasib lived a median of 13.2 months versus 6.7 months for those on chemotherapy.
- 33% of patients experienced tumor shrinkage with daraxonrasib, compared to 11% with chemotherapy. - The drug reduced the risk of death by 60% and doubled progression-free survival.
The findings, published in the New England Journal of Medicine, represent a potential paradigm shift in treating this deadly disease, which has limited effective therapies.